Phase 1 SBO-154 trial of novel MUC1 ADC

This Phase 1 multicenter open-label study evaluates SBO-154, an investigational MUC1 antibody drug conjugate (ADC) for safety, tolerability, and preliminary efficacy in patients with advanced, relapsed, and metastatic solid tumors who have exhausted available standard treatments. Sponsored by Sun Pharma Advanced Research Company Limited, the trial uses multiple dosing regimens to explore optimal strategies for expanding treatment options in this challenging patient population.